Connect with us

Uncategorized

Elixinol CBD Gummies Review

Welcome to our Elixinol CBD Gummies review! Our team tried the Good Mood Assorted CBD Gummies in the 30-count size. While they’re a little on the expensive side, we loved all three flavors and found them moderately relaxing. Elixinol offers three other versions of their Good Mood Gummies, each containing a single flavor of the… View Article

The post Elixinol CBD Gummies Review appeared first on The CBD Insider.

Republished by Plato

Published

on

Elixinol CBD Gummies

Welcome to our Elixinol CBD Gummies review!

Our team tried the Good Mood Assorted CBD Gummies in the 30-count size. While they’re a little on the expensive side, we loved all three flavors and found them moderately relaxing.

Elixinol offers three other versions of their Good Mood Gummies, each containing a single flavor of the three in the assorted jar.

Elixinol Good Mood CBD Gummies: Assorted

Concentration

4-count: 10mg/gummy (40mg total)

30-count: 10mg/gummy (300 mg total)

Price

To check current price, click “Learn More.”

Ingredients

Passion Fruit: Hemp Extract, Cannabidiol, Tapioca Syrup, Sugar, Water, Pectin, Natural Passion Fruit Flavor (ethyl alcohol, water, and natural flavor), Red Color added (concentrated vegetable juice, glycerin, water), Malic Acid (preservative), and Citric Acid (preservative)

Pineapple: Hemp Extract, Cannabidiol, Tapioca Syrup, Sugar, Water, Pectin, Natural Pineapple Flavor (ethyl alcohol, water, and natural flavor), Malic Acid (preservative), and Citric Acid (preservative)

Mixed Berry: Hemp Extract, Cannabidiol, Tapioca Syrup, Sugar, Water, Pectin, Natural Berry Flavor (ethyl alcohol, water, and natural flavor), Blue Color added (glycerin, spirulina extract, water, turmeric, potassium sorbate [preservative], sodium benzoate [preservative]), Malic Acid (preservative), and Citric Acid (preservative)

Elixinol CBD Gummies Review: Table of Contents

  1. Concentration
  2. Value
  3. Packaging
  4. Ingredients
  5. Flavor
  6. Effectiveness
  7. Conclusion
  8. About Elixinol

Concentration

Elixinol’s Good Mood CBD Gummies contain 10mg of CBD from full-spectrum hemp extract per gummy.

According to third-party test results, our gummies had 12.17mg of CBD per gummy.

Compared to the rest of the CBD gummy market, this is an average concentration, but it’s quite low.

Our team has found the most effective concentrations to be at least 25mg per gummy.

Since there are no ingredients to supplement CBD, we believe a higher concentration would be more beneficial.

Value

All Elixinol CBD Gummies cost $39.99 for a 30-count jar, which clocks in at $0.133/mg.

For about a month’s worth of gummies, nearly $40 isn’t bad.

However, when we factor in the low concentration—which begets a high price per mg—these gummies are not quite as cost-efficient as we’d like them to be.

With that said, the effects and tasty flavors are convincing enough to pick these up from time to time.

Elixinol Good Mood Gummies: Mixed Berry

Concentration

4-count: 10mg/gummy (40mg total)

30-count: 10mg/gummy (300mg total)

Price

To check current price, click “Learn More.”

Ingredients

Hemp Extract, Cannabidiol, Tapioca Syrup, Sugar, Water, Pectin, Natural Berry Flavor (ethyl alcohol, water, and natural flavor), Blue Color added (glycerin, spirulina extract, water, turmeric, potassium sorbate [preservative], sodium benzoate [preservative]), Malic Acid (preservative), and Citric Acid (preservative)

Packaging

The gumdrop-shaped gummies come in a small black jar.

If you pick up the assorted gummies, you’ll get a colorful label that contains supplement facts and a disclaimer.

To see the ingredients list, you’ll have to peel off the label, which will also reveal Elixinol’s suggested use information and a QR code to scan for third-party results.

We found it a little confusing that the ingredients were on the back of the label, but it’s a minor nuisance.

Ingredients

Since the assorted gummies contain three different types of CBD gummies, there are different lists of ingredients.

Ingredients for Passion Fruit gummies: Hemp Extract, Cannabidiol, Tapioca Syrup, Sugar, Water, Pectin, Natural Passion Fruit Flavor (ethyl alcohol, water, and natural flavor), Red Color added (concentrated vegetable juice, glycerin, water), Malic Acid (preservative), and Citric Acid (preservative).

Ingredients for Pineapple gummies: Hemp Extract, Cannabidiol, Tapioca Syrup, Sugar, Water, Pectin, Natural Pineapple Flavor (ethyl alcohol, water, and natural flavor), Malic Acid (preservative), and Citric Acid (preservative).

Ingredients for Mixed Berry gummies: Hemp Extract, Cannabidiol, Tapioca Syrup, Sugar, Water, Pectin, Natural Berry Flavor (ethyl alcohol, water, and natural flavor), Blue Color added (glycerin, spirulina extract, water, turmeric, potassium sorbate [preservative], sodium benzoate [preservative]), Malic Acid (preservative), and Citric Acid (preservative).

Overall, Elixinol has made a pretty healthy treat for as healthy as a gummy can be.

The only difference we’d like to see is the addition of supplemental botanicals or herbs that enhance these gummies’ benefits.

Elixinol Good Mood Gummies: Passion Fruit

Concentration

4-count: 10mg/gummy (40mg total)

30-count: 10mg/gummy (300 mg total)

Price

To check current price, click “Learn More.”

Ingredients

Hemp Extract, Cannabidiol, Tapioca Syrup, Sugar, Water, Pectin, Natural Passion Fruit Flavor (ethyl alcohol, water, and natural flavor), Red Color added (concentrated vegetable juice, glycerin, water), Malic Acid (preservative), and Citric Acid (preservative)

Flavor

There are three flavors in the assorted gummies: passion fruit, pineapple, and mixed berry.

While we enjoyed all flavors, which excellently mask the bitterness of hemp, our favorite was pineapple.

The gummies are not chewy; they melted away within a matter of seconds in our mouths.

Effectiveness

Despite the low concentration, we did notice a subtle sense of relaxation that positively affected our mood.

Taking just one gummy produced these effects, but we didn’t notice an increase in the benefits when taking two at a time.

Conclusion

After our Elixinol CBD Gummies review, we consider Elixinol’s first foray into the wide world of CBD gummies to be a successful one.

While certain aspects could be improved, namely the concentration and ingredients, we enjoyed the gummies themselves, especially the flavors.

As a result, we are happy to recommend Elixinol’s Good Mood CBD Gummies.

Elixinol Good Mood CBD Gummies: Pineapple

Concentration

4-count: 10mg/gummy (40mg total)

30-count: 10mg/gummy (300 mg total)

Price

To check current price, click “Learn More.”

Ingredients

Hemp Extract, Cannabidiol, Tapioca Syrup, Sugar, Water, Pectin, Natural Pineapple Flavor (ethyl alcohol, water, and natural flavor), Malic Acid (preservative), and Citric Acid (preservative)

About Elixinol

A vertically integrated company, Elixinol gets its hemp from state-registered farmers in Colorado who grow USDA-certified organic hemp.

As part of their organic certification, Elixinol follows several extensive safety protocols, such as avoiding pesticides or herbicides.

Elixinol uses CO2 to extract oil from the plant’s aerial parts—the parts exposed to air—such as the stem, leaves, and flower.

CO2 is one of the most popular solvents used to extract hemp oil because it does not require filtration, preserving the oil’s purity and leaving no toxic residue.

Elixinol primarily formulates its products with full-spectrum hemp extract, but the brand uses broad-spectrum hemp extract in a few of its products.

In the case of its CBD capsules, Elixinol produces all of them with full-spectrum hemp extract.

Elixinol has all of its products tested by Eurofins, a globally recognized and respected third-party lab headquartered in Luxembourg.

To further verify results, the brand also uses Botanacor, a respected third-party lab based in Denver, Colorado.

Elixinol asks these labs to test its products for cannabinoid potency, residual solvents, heavy metals, pesticides, and microbes.

All Elixinol products have QR codes printed on their labels, allowing consumers to access the brand’s batch testing page quickly.

Consumers can enter the batch number of their product, which is found at the bottom of the Goodnight CBD Capsules bottle, to see the third-party testing results.

In addition to its USDA organic certification, Elixinol has earned a cGMP (current Good Manufacturing Practice) certification and the US Hemp Authority seal from the organization’s certification program.

The brand is also a member of the US Hemp Roundtable, the industry’s most prestigious advocacy body.

The CBD Insider Editorial Team

The mission of The CBD Insider is to provide consumers with a way to find high-quality, safe, and well-formulated CBD products. Our editorial team of passionate industry professionals achieves this mission by providing unbiased, trustworthy, and well-researched reporting about the CBD industry.

Source: https://thecbdinsider.com/uncategorized/elixinol-cbd-gummies-review/

Uncategorized

Aurora Cannabis Inc. Announces US$125 Million Bought Deal Financing

Aurora Cannabis Inc. (“Aurora” or the “Company”) has announced today that it has entered into an agreement with a syndicate of underwriters led by BMO Capital Markets and ATB Capital Markets, under which the underwriters have agreed to buy on bought deal basis 12,000,000 units of the Company (the “Units”), at a price of US$10.45 […]

The post Aurora Cannabis Inc. Announces US$125 Million Bought Deal Financing appeared first on Technical420.

Republished by Plato

Published

on

Aurora Cannabis Inc. (“Aurora” or the “Company”) has announced today that it has entered into an agreement with a syndicate of underwriters led by BMO Capital Markets and ATB Capital Markets, under which the underwriters have agreed to buy on bought deal basis 12,000,000 units of the Company (the “Units”), at a price of US$10.45 per Unit for gross proceeds of approximately US$125 million (the “Offering”). Each Unit will be comprised of one common share of the Company (a “Common Share”) and one half of one common share purchase warrant of the Company (each full common share purchase warrant, a “Warrant”). Each Warrant will be exercisable to acquire one common share of the Company (a “Warrant Share”) for a period of 36 months following the closing date of the Offering at an exercise price of US$12.60 per Warrant Share, subject to adjustment in certain events.

The Company has granted the Underwriters an option, exercisable at the offering price for a period of 30 days following the closing of the Offering, to purchase up to an additional 10% of the Offering to cover over-allotments, if any. This option may be exercised by the Underwriters for additional Units, Common Shares, Warrants or any combination of such securities.

The net proceeds of the offering will be used for general corporate purposes, which may include opportunistically reducing debt. The Company believes that the Offering fits with its broader strategy to have a strong balance sheet while maintaining maximum flexibility to invest and build towards being a leader in global cannabinoids.

The closing of the Offering is expected to take place on or about January 26, 2021 and will be subject to customary conditions, including approvals of the Toronto Stock Exchange and the New York Stock Exchange.

A prospectus supplement (the “Prospectus Supplement”) to the Company’s short form base shelf prospectus dated October 28, 2020 (the “Base Shelf Prospectus”) will be filed with the securities commissions or securities regulatory authorities in each of the provinces of Canada, except Quebec, and with the U.S. Securities and Exchange Commission (the “SEC”) as part of the Company’s registration statement on Form F-10 (the “Registration Statement”) under the U.S./Canada Multijurisdictional Disclosure System. The Prospectus Supplement, the Base Shelf Prospectus and the Registration Statement contain important detailed information about the Company and the proposed Offering. Prospective investors should read the Prospectus Supplement, the Base Shelf Prospectus and the Registration Statement and the other documents the Company has filed for more complete information about the Company and this Offering before making an investment decision.

Copies of the Prospectus Supplement, following filing thereof, and the Base Shelf Prospectus will be available on SEDAR at www.sedar.com and copies of the Prospectus Supplement and the Registration Statement will be available on EDGAR at www.sec.gov . Copies of the Prospectus Supplement, following filing thereof, the Base Shelf Prospectus and the Registration Statement may also be obtained from BMO Capital Markets by contacting BMO Capital Markets, Brampton Distribution Centre C/O The Data Group of Companies, 9195 Torbram Road, Brampton, Ontario, L6S 6H2 or by telephone at (905) 791-3151 Ext 431 or by email at torbramwarehouse@datagroup.ca or from BMO Capital Markets Corp., Attn: Equity Syndicate Department, 3 Times Square, 25th Floor, New York, NY 10036 (Attn: Equity Syndicate), or by telephone at (800) 414-3627 or by email atbmoprospectus@bmo.com . Copies of such documents may also be obtained from ATB Capital Markets Inc., Attn: Gail O’Connor, 410-585 8th Ave SW, Calgary, Alberta, T2P 1G1, (403) 539-8629 or by email from atbcm_dealflow@atb.com .

No securities regulatory authority has either approved or disapproved of the contents of this press release. This press release is for information purposes only and shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Aurora

Aurora is a global leader in the cannabis industry serving both the medical and consumer markets. Headquartered in Edmonton, Alberta, Aurora is a pioneer in global cannabis dedicated to helping people improve their lives. The Company’s brand portfolio includes Aurora, Aurora Drift, San Rafael ‘71, Daily Special, AltaVie, MedReleaf, CanniMed, Whistler, and Reliva CBD. Providing customers with innovative, high-quality cannabis products, Aurora’s brands continue to break through as industry leaders in the medical, performance, wellness and recreational markets wherever they are launched. For more information, please visit our website at www.auroramj.com .

Aurora’s common shares trade on the TSX and NYSE under the symbol “ACB”, and is a constituent of the S&P/TSX Composite Index.

Further Information

For Media: For Investors:
Michelle Lefler ICR, Inc.
VP, Communications & PR Investor Relations
media@auroramj.com aurora@icrinc.com

Forward Looking Statements

This news release includes statements containing certain “forward-looking information” within the meaning of applicable securities law (“forward-looking statements “). Forward-looking statements are frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. Forward-looking statements made in this news release include statements regarding: the timing and completion of the Offering and the expected use of proceeds of the Offering. These forward-looking statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward looking statements are based on the opinions, estimates and assumptions of management in light of management’s experience and perception of historical trends, current conditions and expected developments at the date the statements are made, such as current and future market conditions, the ability to maintain SG&A costs in line with current expectations, the ability to achieve high margin revenues in the Canadian consumer market, the current and future regulatory environment and future approvals and permits. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements, including the risks associated with: entering the U.S. market, the ability to realize the anticipated benefits associated with the acquisition of Reliva, achievement of Aurora’s business transformation plan, general business and economic conditions, changes in laws and regulations, product demand, changes in prices of required commodities, competition, the effects of and responses to the COVID-19 pandemic and other risks, uncertainties and factors set out under the heading “Risk Factors” in the Company’s annual information form dated September 24, 2020 (the “ AIF ”) and filed with Canadian securities regulators available on the Company’s issuer profile on SEDAR at www.sedar.com and filed with and available on the SEC’s website at www.edgar.gov. The Company cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.


Primary Logo Source: https://technical420.com/cannabis-article/aurora-cannabis-inc-announces-us125-million-bought-deal-financing/

Continue Reading

Uncategorized

The Biden Presidency Looks To Be Installing Several Pro-Cannabis People Into Key Roles In Government

After Kamala Harris was nominated to be President Elect Joe Biden’s running mate, we knew that brighter days were ahead for the cannabis industry……..and the market seemed to agree with us. After Joe Biden was projected to win the election, the cannabis sector recorded strong moves to the upside for almost two months. Although the […]

The post The Biden Presidency Looks To Be Installing Several Pro-Cannabis People Into Key Roles In Government appeared first on Technical420.

Republished by Plato

Published

on

After Kamala Harris was nominated to be President Elect Joe Biden’s running mate, we knew that brighter days were ahead for the cannabis industry……..and the market seemed to agree with us.

After Joe Biden was projected to win the election, the cannabis sector recorded strong moves to the upside for almost two months. Although the sector has come off its recent highs, we believe the recent additions to President Elect Joe Biden’s cabinet send a very bullish sign to the cannabis industry.

During the last month, President Elect Joe Biden has announced several key cannabis-friendly additions to his cabinet. When you combine the democrats winning two key senate seats in Georgia (and became the majority of both the House of Representatives and the Senate) with the recent additions to the cabinet, we believe that the US cannabis industry is going to flourish.

Most recently, President elect Joe Biden selected former South Carolina Democratic Party Chair Jaime Harrison to lead the Democratic National Committee (DNC). He is a strong supporter of cannabis legalization and will be responsible for coordinating Democrats’ national political activities. Harrison still needs to be confirmed by party leaders, but we are confident that he will.

When Harrison ran for a Senate seat in South Carolina, he said that the US should legalize, regulate and tax cannabis like alcohol and tobacco. We are favorable on his appointment and believe that his views on cannabis will be reflected in the Democrats’ national political activities.

While we can hope for the legalization of cannabis the federal level, we believe the new administration (and government) will quickly pass cannabis decriminalization legislation. If we see cannabis decriminalized, we believe that companies will quickly notice significant margin appreciation. If cannabis is decriminalized, 280 E should be revoked, and this would prove to be a substantial catalyst for companies.

280E is the worst legislation we have ever seen in any industry. The rule does not allow companies to deduct basic business expenses and makes it much more challenging for operators to reach profitability. We believe the revoking of 280E is inevitable and is something that our readers should be aware of.

Share Share - Facebook Share - Twitter

Authored By

Michael Berger

Michael Berger is Managing Partner of StoneBridge Partners LLC. SBP continues to drive market awareness for leading firms in the cannabis industry throughout the U.S. and abroad.

Source: https://technical420.com/cannabis-article/the-biden-presidency-looks-to-be-installing-several-pro-cannabis-people-into-key-roles-in-government/

Continue Reading

Uncategorized

MustGrow Achieves 100% Control of Root-Rot Disease Infecting Key Plant-Based Protein Crops

MustGrow Biologics Corp. (CSE: MGRO) (OTC: MGROF) (FSE: 0C0) is pleased to announce successful laboratory test results of its patented mustard-derived biopesticide on Aphanomyces euteiches zoospores (“Aphanomyces“) via an independent third party facility: 100% control at economic application rates within 24 hours. MustGrow will now advance to larger scale greenhouse and field tests. Study results […]

The post MustGrow Achieves 100% Control of Root-Rot Disease Infecting Key Plant-Based Protein Crops appeared first on Technical420.

Republished by Plato

Published

on

MustGrow Biologics Corp. (CSE: MGRO) (OTC: MGROF) (FSE: 0C0) is pleased to announce successful laboratory test results of its patented mustard-derived biopesticide on Aphanomyces euteiches zoospores (“Aphanomyces“) via an independent third party facility: 100% control at economic application rates within 24 hours. MustGrow will now advance to larger scale greenhouse and field tests. Study results and applicability are patent-protected under MustGrow’s existing suite of issued patents.

MustGrow’s remarkably safe and effective organic biopesticide is plant-based – harnessing the mustard seed’s natural defense mechanism to control diseases, pests, and weeds with an organic food-grade biopesticide.

Aphanomyces is a water mould pathogen responsible for root-rot disease, infecting a variety of peas, lentils and other legumes collectively referred to as pulse crops. The disease causes severe root damage and wilting, with yield losses ranging from 10% to 100% in infected fields (1). Canada is one of the world’s largest producers (~9.2 million tons; 2019) and exporters of pulse crops (2). Industry experts conservatively estimate $20 million in annual pulse crop losses in Canada and $100 million globally caused by Aphanomyces (1). Current treatment measures cannot control Aphanomyces – they are only able to slow down the spread and reduce the incidence and severity of the disease.

“It is great to see MustGrow’s mustard plant-based biopesticide continue to perform, particularly with 100% disease control measured at exceptionally low application rates. The level of control of hard-to-kill diseases we continue to achieve combined with the beneficial properties of our product for soil health provide a great opportunity for improved yields for farmers and a more robust food supply,” remarked Colin Bletsky, COO of MustGrow. “I am very hopeful that we can potentially provide a valuable crop-protection tool for pulse crop farmers.”

Plant-Based Crop Protection for Plant-Based Protein

MustGrow feels it makes both logical and ecological sense to protect plant-based protein crops with plant-based crop protection inputs. MustGrow’s product is a pre-plant soil treatment, meaning application to the soil occurs before crops are planted. Application of MustGrow’s biopesticide returns organic plant material to the soil through this pre-plant treatment process as a potential alternative to using synthetic chemicals.

According to MarketsandMarkets and analysis by EY-Parthenon, the global plant-based protein market size is projected to grow from US$12 billion in 2019 to US$28 billion by 2025 (CAGR of 15%). This is attributed to several drivers, predominantly rising consumer health-consciousness, growing prevalence of protein-rich pulse crop food products, and technological innovations in plant-based protein extraction. To accommodate the rise of plant-based protein demand, Fior Markets estimates the global pulse crops market will grow from US$16.2 billion in 2017 to US$24.3 billion by 2025 (CAGR of 5.2%).

The interest in MustGrow’s plant-based biopesticide is increasing as farmers, consumers and investors seek ‘natural biological’ alternatives to synthetic chemical pesticides. Adverse global climate and weather events are expected to negatively impact food supply for a growing human population. Warmer temperatures are expected to increase pest infestations and with more pests there will be more damage to crops. The development of safe and effective biopesticides will be critical for future food security and environmentally sustainable agriculture.

Sources:
(1) Globenewswire, 3rd party market research, MustGrow estimates
(2) imarcgroup.com

About MustGrow

MustGrow is a publicly traded (CSE: MGRO) (OTC: MGROF) (FSE: 0C0) agriculture biotech company focused on providing natural science-based biological solutions for high value crops, including fruits & vegetables and other industries. MustGrow has designed and owns a U.S. EPA-approved natural solution that uses the mustard seed’s natural defence mechanism to protect plants from pests and diseases. Over 110 independent tests have been completed, validating MustGrow’s safe and effective signature products. The product, in granule format, is EPA-approved across all key U.S. states and by Health Canada’s PMRA (Pest Management Regulatory Agency) as a biopesticide for high value crops such as in fruit & vegetables. MustGrow has now concentrated a liquid format, TerraMG, and with regulatory approval, could be applied through standard drip or spray equipment, improving functionality and performance features. In addition, this new mustard-derived technology could have other applications in several different industries from pre-plant soil treatment to post harvest pest and disease control.

The Company has approximately 40.7 million basic common shares issued and outstanding and 50.6 million shares fully diluted. For further details please visit www.mustgrow.ca.

ON BEHALF OF THE BOARD

“Corey Giasson”

Director & CEO
Phone: +1-306-668-2652
info@mustgrow.ca

Forward-Looking Statements

Certain statements included in this press release constitute “forward-looking statements” which involve known and unknown risks, uncertainties and other factors that may affect the results, performance or achievements of MustGrow.

Generally, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “expects”, “is expected”, “budget”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might”, “occur” or “be achieved”.

Forward-looking statements are subject to a number of risks and uncertainties that may cause the actual results of MustGrow to differ materially from those discussed in such forward-looking statements, and even if such actual results are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on, MustGrow.

These risks are described in more detail in MustGrow’s Prospectus and other continuous disclosure documents filed by MustGrow with the applicable securities regulatory authorities and available at www.sedar.com. Readers are referred to such documents for more detailed information about MustGrow, which is subject to the qualifications, assumptions and notes set forth therein.

This release does not constitute an offer for sale of, nor a solicitation for offers to buy, any securities in the United States.

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

© 2021 MustGrow Biologics Corp. All rights reserved.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/72356

Source: https://technical420.com/cannabis-article/mustgrow-achieves-100-control-of-root-rot-disease-infecting-key-plant-based-protein-crops/

Continue Reading
News13 hours ago

Jay-Z Announces Launch of Investment Fund To Aid Minority Cannabis Entrepreneurs

News5 days ago

What are Some Major Factors to Keep in Mind When Buying CBD Vape Oil?

Heartland2 days ago

MagicMed: Bringing the Drug Candidate Library Model to Psychedelics

Heartland5 days ago

Investors in This Cannabis Stock Are Leaving $800 Million on the Table

Heartland5 days ago

What’s New With Cannabis Stocks for the Week Ending 01/15/21

Heartland4 days ago

What is Delta-8 THC? Everything You Need to Know

Heartland4 days ago

Alcanna to Spin Out Cannabis Business and Pursue Value Segment Strategy

Heartland1 day ago

10 Herbs That Can Help With Sleep

News4 days ago

CBD News: NIHC chairman appointed to board advising U.S. on trade policy

Heartland14 hours ago

Anybody ever bought from highkind? Review?

Heartland4 days ago

Fire & Flower Expands Free Same-Day Delivery Across Its Ontario Network

Heartland3 days ago

Heavy metals in cbd

News3 days ago

CBD News: Restrictions on shipment of vaping products could impact hemp industry

Heartland3 days ago

CBD Blog: News, Info & Tips

Heartland2 days ago

Nordic Oil FAQ: The CBD questions you’ve always wanted answers to

Heartland3 days ago

Informational blogs about CBD and Hemp

Heartland3 days ago

Hemp & CBD Blog | Northeast Kingdom Hemp

Heartland4 days ago

A Beginners Guide to Pests

News3 days ago

Illinois Collects $62 Million in Cannabis Revenue to Support Neighborhoods

Heartland3 days ago

Blog – Global Cannabinoids | CBD Wholesale & Bulk | White Label | Private Label

Heartland1 day ago

19 in texas I know it is technically legal to possess hemp flower I’m wondering about the penalties of possession under 21

Heartland4 days ago

Clinical and biochemical heterogeneity of Parkinson’s disease

Heartland3 days ago

Heartland3 days ago

CBD Blogs | Ergo Hemp Co.

Heartland14 hours ago

Cannabis Antibiotics: Answer to Disease-Resistant Bacteria

Heartland3 days ago

Easy Day Hemp Blog

News4 days ago

BC Craft Supply Co Announces Letter of Intent with Psilocybin Research and Development Company Ava Pathways

Heartland4 days ago

How Red White & Bloom Established A Base In Michigan’s Cannabis Scene—And Keeps Expanding

News3 days ago

CBD News: Circle K wants to block hemp trademark that resembles its own

Uncategorized3 days ago

10xPURE-GOLD CBDa Muscle & Joint Relief Cream

Trending

A Cloud Nine Capital Entity Copyright © 2020 – All Rights Reserved Proudly Made in America